216 related articles for article (PubMed ID: 19535781)
1. Value of adding single-nucleotide polymorphism genotypes to a breast cancer risk model.
Gail MH
J Natl Cancer Inst; 2009 Jul; 101(13):959-63. PubMed ID: 19535781
[TBL] [Abstract][Full Text] [Related]
2. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk.
Gail MH
J Natl Cancer Inst; 2008 Jul; 100(14):1037-41. PubMed ID: 18612136
[TBL] [Abstract][Full Text] [Related]
3. Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women.
McCarthy AM; Armstrong K; Handorf E; Boghossian L; Jones M; Chen J; Demeter MB; McGuire E; Conant EF; Domchek SM
Breast Cancer Res Treat; 2013 Apr; 138(3):889-98. PubMed ID: 23474973
[TBL] [Abstract][Full Text] [Related]
4. The use of the Gail model, body mass index and SNPs to predict breast cancer among women with abnormal (BI-RADS 4) mammograms.
McCarthy AM; Keller B; Kontos D; Boghossian L; McGuire E; Bristol M; Chen J; Domchek S; Armstrong K
Breast Cancer Res; 2015 Jan; 17(1):1. PubMed ID: 25567532
[TBL] [Abstract][Full Text] [Related]
5. Assessment of clinical validity of a breast cancer risk model combining genetic and clinical information.
Mealiffe ME; Stokowski RP; Rhees BK; Prentice RL; Pettinger M; Hinds DA
J Natl Cancer Inst; 2010 Nov; 102(21):1618-27. PubMed ID: 20956782
[TBL] [Abstract][Full Text] [Related]
6. Twenty-five years of breast cancer risk models and their applications.
Gail MH
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25722355
[No Abstract] [Full Text] [Related]
7. Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model.
Dite GS; Mahmoodi M; Bickerstaffe A; Hammet F; Macinnis RJ; Tsimiklis H; Dowty JG; Apicella C; Phillips KA; Giles GG; Southey MC; Hopper JL
Breast Cancer Res Treat; 2013 Jun; 139(3):887-96. PubMed ID: 23774992
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk prediction and mammography biopsy decisions: a model-based study.
Armstrong K; Handorf EA; Chen J; Bristol Demeter MN
Am J Prev Med; 2013 Jan; 44(1):15-22. PubMed ID: 23253645
[TBL] [Abstract][Full Text] [Related]
9. A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
Vachon CM; Schaid DJ; Ingle JN; Wickerham DL; Kubo M; Mushiroda T; Goetz MP; Carlson EE; Paik S; Wolmark N; Nakamura Y; Wang L; Weinshilboum R; Couch FJ
Breast Cancer Res Treat; 2015 Jan; 149(2):517-23. PubMed ID: 25575444
[TBL] [Abstract][Full Text] [Related]
10. News media coverage of screening mammography for women in their 40s and tamoxifen for primary prevention of breast cancer.
Schwartz LM; Woloshin S
JAMA; 2002 Jun; 287(23):3136-42. PubMed ID: 12069679
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement.
Darabi H; Czene K; Zhao W; Liu J; Hall P; Humphreys K
Breast Cancer Res; 2012 Feb; 14(1):R25. PubMed ID: 22314178
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen and breast density in women at increased risk of breast cancer.
Cuzick J; Warwick J; Pinney E; Warren RM; Duffy SW
J Natl Cancer Inst; 2004 Apr; 96(8):621-8. PubMed ID: 15100340
[TBL] [Abstract][Full Text] [Related]
13. 10-year performance of four models of breast cancer risk: a validation study.
Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
[TBL] [Abstract][Full Text] [Related]
15. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen.
Atkinson C; Warren R; Bingham SA; Day NE
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):863-6. PubMed ID: 10548313
[TBL] [Abstract][Full Text] [Related]
16. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening.
Eriksson M; Czene K; Strand F; Zackrisson S; Lindholm P; Lång K; Förnvik D; Sartor H; Mavaddat N; Easton D; Hall P
Radiology; 2020 Nov; 297(2):327-333. PubMed ID: 32897160
[TBL] [Abstract][Full Text] [Related]
17. The prevention, detection, and management of breast cancer.
Houssami N; Cuzick J; Dixon JM
Med J Aust; 2006 Mar; 184(5):230-4. PubMed ID: 16515434
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer.
Nyante SJ; Sherman ME; Pfeiffer RM; Berrington de Gonzalez A; Brinton LA; Aiello Bowles EJ; Hoover RN; Glass A; Gierach GL
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25663687
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.
Quante AS; Whittemore AS; Shriver T; Strauch K; Terry MB
Breast Cancer Res; 2012 Nov; 14(6):R144. PubMed ID: 23127309
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
